newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative